Michael T. Stocum

American Association for Clinical Chemistry, Inc. (AACC) is a scientific and medical professional organization that focuses on clinical laboratory science and its application to healthcare. The organization is based in Washington and was founded in 1948. AACC provides leadership in education, advocacy, and collaboration to help lab professionals adapt to change and provide vital insight and guidance for patient care. The organization offers accreditation programs, press releases, media advisories, and statements that spotlight scientific, clinical, and technological breakthroughs. AACC has a longstanding commitment to provide customers with the best possible experience every time they use the AACC website. Mark J. Golden has been the CEO of the American company since 2020.

BioFluidica, Inc. is a biotechnology company specializing in the development of diagnostic platform for disease management. It captures and isolates disease biomarkers, such as Circulating Tumor Cells. The company was founded by Steven A. Soper in 2007 and is headquartered in San Diego, CA.

Bantam Pharmaceutical LLC is a privately funded biopharmaceutical company that specializes in the discovery and development of novel therapeutics for difficult-to-treat hematological and solid tumors. The company is based in New York, NY. The company is currently pursuing an IND application for its lead candidate, BTM-3566, in B-cell malignancies. Bantam's clinical development strategy is focused on areas of unmet clinical need, with initial phase I/II clinical trials planned in relapsed/refractory B-cell hematological malignancies, including diffuse large B-cell lymphoma. The company was founded by Victor F. Keen, and Michael T. Stocum has been the CEO of the company since 2019.

Inivata Ltd. develops new clinical applications for ctDNA analysis. It is a clinical cancer genomics company harnessing the potential of circulating tumour DNA (ctDNA) analysis to improve cancer testing and treatment. The firm is focused on developing clinical applications of ctDNA through collaborations with clinical oncologists at prominent academic institutions, leading community treatment centres and innovative biopharmaceutical companies. The company was founded by James Brenton, Tim Forshew, Rosenfeld Nitzan and Davina Gale on July 23, 2014 and is headquartered in Cambridge, the United Kingdom.

On-Q-ity is an innovative diagnostic company that is focused on providing physicians with the tools they need to make the best decision when treating individual cancer patients. Its circulating tumor cell technology will enable better decision-making across multiple cancers: improving the quality of life for patients and ultimately increasing survival. On-Q-ity's products and services are based on its unique and proprietary circulating tumor cell (CTC) technology which enables them to capture, count and characterize CTCs from a sample of patient blood. Through proprietary circulating tumor cell (CTC) and biomarker technology, they are creating products designed to non-invasively monitor and optimize cancer care throughout the disease cycle. They invite companies with complementary technologies, innovative biomarkers, and special expertise in its field to explore partnering relationships.